TIPSLIFEHACKS

Altimmune Explores Obesity Drug Pemvidutide for Alcohol Use Disorder Treatment

Reuters

Altimmune announces plans to investigate its lead obesity treatment, pemvidutide, for potential use in treating alcohol use disorder and associated liver disease, offering new hope for those struggling with addiction and related health issues. This innovative approach may provide a breakthrough in addressing the complex relationship between obesity, alcohol consumption, and liver health. By repurposing its obesity drug, Altimmune aims to tackle the growing concerns of alcohol use disorder and its impact on public health. With this promising development, the company is poised to make a significant impact in the medical community.